Kura Oncology, Inc.
Here’s whether Kura Oncology, Inc. (KURA) is worth buying in 2026 — based on weekly-updated price trend, RSI momentum, and return vs. the S&P 500. Our current read: Bullish.
Positives: trading above the 200-day MA (long-term uptrend intact); above the 50-day MA (medium-term momentum positive); 50-day MA is rising (+1.29% over 10 days); strong 1-year return of +68.3%; 3-month momentum positive (+14.4%). Concerns: RSI 82 — overbought, elevated pullback risk. Currently 22.5% off its 52-week high. Score: +5/7.
KURA is in a confirmed uptrend, trading above both its 50-day ($8.51) and 200-day ($8.76) moving averages. With an RSI of 82.1, momentum has stretched into overbought territory — short-term pullbacks are common from these levels. The 1-year return of +68.3% compares to +35.1% for SPY (beat the market by 33.3%). The current 22.5% drawdown from the 52-week high reflects elevated risk for momentum-based strategies.